Investor profile
Gilde Healthcare
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Gilde Healthcare is a specialist private investment firm with €3 billion under management across three fund strategies: Venture & Growth in Healthcare, Private Equity in Healthcare, and Private Equity in Climate Solutions. The firm's stated mission is to invest in companies that enable 'better care at lower cost.' The Venture & Growth fund targets fast-growing, innovative companies active in digital health, medtech, and therapeutics based in Europe and North America, with typical investments of €10–70 million per new portfolio company. The Private Equity fund focuses on profitable lower mid-market healthcare companies in North-Western Europe — including healthcare providers, medical product suppliers, and service providers — leveraging deep sector expertise and a transatlantic network built over more than two decades.
Notable quotes
“The strong interest from institutional investors driven to make a substantial impact, is a clear endorsement of our mission: investing in solutions to improve the quality of patient care while keeping it affordable. Our broad strategy, covering digital health, MedTech and therapeutics, results in a holistic approach allowing us to select the most optimal and cost effective solution for the individual patient.”
“I am excited to join Gilde Healthcare and work alongside a team of highly skilled professionals who are committed to making a difference in the healthcare industry. Gilde Healthcare's dedication to investing in companies that drive positive change aligns perfectly with my passion for advancing healthcare through innovative solutions.”
“Gilde believed in Inari at a time few other investors did. They were an exceptional partner to Inari as we expanded our life-saving treatment throughout the US and the world.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| GT Medical Technologies (GammaTile) | Series E | $61m | 2026-06 |
| Adcendo | Series C | $157m | 2026-04 |
| Endovascular Engineering | Series C | $29m | 2026-04 |
| BigHealth | Series C | $39m | 2026-02 |
| SpliceBio | Series B | $135m | 2024-01 |
| Purespring Therapeutics | Series B | $101m | 2023-10 |
| Inari Medical | Series C | $27m | 2018-03 |
| Withings | Growth | — | — |
| Noema Pharma | Series B | $147m | 2022-01 |
| Ascendis Pharma | Venture | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Forbion | 5 |
| Sofinnova Partners | 4 |
| EQT Life Sciences | 3 |
| Jeito Capital | 3 |
| Syncona | 2 |
| New Enterprise Associates (NEA) | 2 |
Fit check
Is Gilde Healthcare a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit